We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

PamGene Enters Co-Marketing Agreement with Invitrogen in Nuclear Hormone Receptor Drug Discovery

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

PamGene International BV has announced the signing of a co-marketing agreement with Invitrogen Corporation a provider of essential life science technologies for research, production and diagnostics.

Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen's Nuclear Hormone Receptor proteins and Lanthascreen® assay technology with PamGene's portfolio of microarray-based Nuclear Hormone Receptor screening tools; specifically its PamChip® applications and PamStation® instrumentation.

This creates a complete offering for compound screening in drug discovery in the areas of cancer, diabetes and heart disease. The current market for nuclear receptor targeted drugs is estimated to be 10-15% of the $400 billion global pharmaceutical market.